The latest news from academia, regulators
research labs and other things of interest
Posted: Oct 29, 2013
Nanotechnology Award: winners of the best international nanomedicine innovation 2013
(Nanowerk News) Since the official launch in June 2013, the European Technology Platform for Nanomedicine (ETPN) together with the EU funded consortium NANOMED2020, are organising the first ever Nanomedicine Award to honor the best international nanomedicine innovation for 2013.
The call for applications ended on September 7th gathering overall 23 candidatures coming from all over the world: from Europe but also from Australia and the US. Gathering academia and SMEs, and covering all three fields of diagnostics and imaging, therapeutics and regenerative medicine, this first edition is seen as a success holding great promises for the coming years.
The Award winners will be officially announced during the Nanomedicine Panel Session at BIO-Europe® 2103 in Vienna on 4th November. Projects have since been reviewed and assessed by a panel of highly-qualified pharma industry specialists with experience in R&D and commercial roles: Laurent Levy, Nanobiotix; Neil Desai, Celgene; Mike Eaton, consultant; Patrick Tricoli, Sanofi; Karen Zinkevich-Peotti, Ipsen and Thorsten Melcher, Johnson & Johnson Innovation.
For the second time at BIO-Europe, a session is especially dedicated to the field of nanomedicine, representing a major opportunity to increase the visibility and synergies of the field with the pharmaceutical industries, a crucial stakeholder in the development of nanotherapeutics towards the patients.
The winners will receive media coverage across Europe and gain visibility to EU decision makers from biotechnology, pharma, academia and finance. Winners will also benefit from a full registration (including partnering) for BIO-Europe 2013 and a 5-minute presentation slot at the Nanomedicine Panel Discussion during the event. In addition, the winning project will also be granted a 15-minute presentation slot during the CLINAM conference 2014 in Basel, Switzerland, along with 1 year’s free ETPN membership and two days consultation by the members of the ETPN Translational Advisory Board.
About ETP Nanomedicine
The European Technology Platform Nanomedicine was established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe. The ETPN contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States. www.ebdgroup.com
About BIO-EUROPE 2013
The 19th annual BIO-Europe® event will be the largest biotechnology partnering conference held in Europe. Over 3,000 global decision makers from biotechnology, pharma and finance, representing upwards of 1,700 companies from over 50 countries, annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe will take place November 4–6, 2013 in Vienna, Austria. www.ebdgroup.com/bioeurope
Source: VDI/VDE Innovation + Technik
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!
Check out these other trending stories on Nanowerk: